News from provention bio, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 13, 2023, 07:00 ET Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it ...

Mar 03, 2023, 16:05 ET Provention Bio Announces the Grant of Inducement Awards

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Feb 23, 2023, 08:30 ET Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Feb 13, 2023, 07:30 ET Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Feb 08, 2023, 07:30 ET Provention Bio to Present at the SVB Securities Global Biopharma Conference

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced...

Feb 03, 2023, 16:01 ET Provention Bio Announces the Grant of Inducement Awards

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Feb 02, 2023, 16:01 ET Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD®

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Jan 06, 2023, 16:01 ET Provention Bio Announces the Grant of Inducement Awards

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Jan 05, 2023, 16:01 ET Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Dec 02, 2022, 16:01 ET Provention Bio Announces the Grant of Inducement Awards

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Nov 17, 2022, 17:45 ET TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Nov 04, 2022, 16:05 ET Provention Bio Announces the Grant of Inducement Awards

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Nov 03, 2022, 07:00 ET Provention Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported...

Oct 13, 2022, 07:30 ET Provention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Oct 07, 2022, 16:01 ET Provention Bio Announces the Grant of Inducement Awards

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Oct 06, 2022, 07:00 ET Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Sep 19, 2022, 07:30 ET Provention Bio Announces Senior Leadership Addition

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Sep 06, 2022, 16:01 ET Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Sep 02, 2022, 16:01 ET Provention Bio Announces the Grant of Inducement Awards

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Aug 31, 2022, 18:12 ET Provention Bio Announces $125 Million Term Loan Facility with Hercules Capital

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Aug 04, 2022, 07:00 ET Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported...

Aug 02, 2022, 16:05 ET Provention Bio Announces the Grant of Inducement Awards

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Jul 28, 2022, 07:30 ET Provention Bio to Report Second Quarter 2022 Financial Results on August 4, 2022

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Jul 07, 2022, 19:28 ET Provention Bio Announces $60 Million Private Placement

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Jul 05, 2022, 16:01 ET Provention Bio Announces the Grant of Inducement Awards

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...